News Category
Helus Pharma's appointment of veteran biopharmaceutical leader Michael Halstead as CEO signals strategic focus on advancing its lead candidate HLP003 ...
Luke Van Der Veer's Website Rental Coaching program, teaching local SEO and 'Rank and Rent' strategies, now serves 467 students across 14 countries, e...
Ireland's new Mental Health Act bans electroconvulsive therapy for individuals under 18, a move advocates hope will lead to broader restrictions on th...
Helus Pharma announced fiscal 2026 financial results, highlighting that its Phase 3 APPROACH trial for HLP003 in major depressive disorder has surpass...
Helus Pharma raised $50 million in an underwritten public offering to fund Phase 3 trials for major depressive disorder and other pipeline assets, mar...
Helus Pharma announced the pricing of a $50 million public offering to fund Phase 3 and Phase 2 trials for novel treatments for major depressive disor...
Helus Pharma announced that enrollment in its Phase 3 APPROACH trial for HLP003, a novel serotonergic agonist with Breakthrough Therapy Designation, h...
Helus Pharma's participation in the H.C. Wainwright conference highlights its progress in developing novel serotonergic agonists for mental health con...
Craig Munro Wilson's 'Baptize America' examines the 1820 Campbell-Walker debate, arguing it was a pivotal moment that defined American Christianity's ...
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions but con...
Helus Pharma strengthens its Scientific Advisory Board with renowned experts in biotechnology and CNS clinical development as it advances novel seroto...
Michael Cola has stepped down as CEO of Helus Pharma, with Executive Chairman Eric So named interim leader as the company advances its Phase 3 trial f...
Helus Pharma announced the appointment of Dr. Ken Kramer as senior vice president of medical affairs, bringing over 20 years of neuroscience leadershi...
The launch of a data center near Dublin operating independently from the national grid via a microgrid marks a significant step in addressing the ener...
Helus Pharma announced positive Phase 2 results for HLP004, showing significant anxiety reduction in GAD patients with limited treatment options, supp...
The appointment of Dr. Freda Lewis-Hall, a seasoned biopharmaceutical executive with over 40 years of experience, to Helus Pharma's board and as chair...
Helus Pharma announced that its Phase 2a trial data for SPL026, published in Nature Medicine, demonstrated statistically significant and clinically me...
Helus Pharma's Q3 2025 financial results show a strong cash position and progress in its Phase 3 and Phase 2 clinical trials for major depressive diso...
Helus Pharma announced Michael Cola as CEO to lead the company through upcoming Phase 2 and Phase 3 data readouts for its novel serotonergic agonists ...
The branded merchandise franchise saw increased systemwide sales, 57 new franchise agreements, and expansion into India, Ireland, and Cameroon, driven...
Exit Factor plans to enter new international markets in 2026, including New Zealand, Canada, Ireland, and the Netherlands, after launching 66 U.S. ter...
